BRIGHT MINDS BIOSCIENCES INVESTIGATION: DRUG Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK, Nov. 04, 2026 -- The law firm of Kirby McInerney LLP is investigating potential claims against Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Bright Minds securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.